81 related articles for article (PubMed ID: 11357487)
1. Comments to: Yudkin J, Panahloo A, Stenhouwer C et al. (2000) the influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in type II diabetic subjects. Diabetologia 43: 1099-1106.
Ebeling P; Heliövaara MK
Diabetologia; 2001 Apr; 44(4):519-20. PubMed ID: 11357487
[No Abstract] [Full Text] [Related]
2. Comments to: Yudkin J, Panahloo A, Stenhouwer C et al. (2000) the influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in type II diabetic subjects. Diabetologia 43: 1099-1106.
Fernandez-Real JM; Ricart W
Diabetologia; 2001 Apr; 44(4):518-9. PubMed ID: 11357486
[No Abstract] [Full Text] [Related]
3. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects.
Yudkin JS; Panahloo A; Stehouwer C; Emeis JJ; Bulmer K; Mohamed-Ali V; Denver AE
Diabetologia; 2000 Sep; 43(9):1099-106. PubMed ID: 11043855
[TBL] [Abstract][Full Text] [Related]
4. When to use insulin in the maturity onset diabetic.
Tattersall RB; Scott AR
Postgrad Med J; 1987 Oct; 63(744):859-64. PubMed ID: 3328848
[No Abstract] [Full Text] [Related]
5. To: Strey CH, Young J, Collier M, Florkowski CM, Shand BI, Scott RS (2004) The postprandial state does not impair endothelial function in women with Type 2 diabetes irrespective of glycaemic control. Diabetologia 47:1838-1846.
Ceriello A; Hanefeld M; Leiter L; Monnier L; Owens D; Tajima N; Tuomilehto J
Diabetologia; 2005 Jul; 48(7):1423-4; author reply 1425-6. PubMed ID: 15947911
[No Abstract] [Full Text] [Related]
6. Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients.
Knöbl P; Schernthaner G; Schnack C; Pietschmann P; Proidl S; Prager R; Vukovich T
Thromb Haemost; 1994 Jun; 71(6):692-7. PubMed ID: 7974333
[TBL] [Abstract][Full Text] [Related]
7. Glycaemic control in type 2 diabetes.
Campbell A
Clin Evid; 2005 Dec; (14):474-90. PubMed ID: 16620416
[No Abstract] [Full Text] [Related]
8. Combination insulin-sulfonylurea therapy in type II diabetes mellitus.
Allen BT; Feinglos MN
South Med J; 1987 Oct; 80(10):1285-9. PubMed ID: 3310252
[No Abstract] [Full Text] [Related]
9. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
Johnson JL; Wolf SL; Kabadi UM
Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
[TBL] [Abstract][Full Text] [Related]
10. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2.
Forst T; Lübben G; Hohberg C; Kann P; Sachara C; Gottschall V; Friedrich C; Rosskopf R; Pfützner A
Microcirculation; 2005; 12(7):543-50. PubMed ID: 16207627
[TBL] [Abstract][Full Text] [Related]
11. [Transdermal administration of insulin in type II diabetics. Results of a clinical pilot study].
Liedtke RK; Sorger M; Merk F; Vetter H
Arzneimittelforschung; 1990 Aug; 40(8):884-6. PubMed ID: 2242080
[TBL] [Abstract][Full Text] [Related]
12. Effect of acute hyperglycaemia, long-term glycaemic control and insulin on endothelial dysfunction and inflammation in Type 1 diabetic patients with different characteristics.
Ceriello A; Esposito K; Ihnat M; Thorpe J; Giugliano D
Diabet Med; 2010 Aug; 27(8):911-7. PubMed ID: 20653749
[TBL] [Abstract][Full Text] [Related]
13. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes.
Olsson PO; Lindström T
Diabetes Metab; 2002 Sep; 28(4 Pt 1):272-7. PubMed ID: 12442064
[TBL] [Abstract][Full Text] [Related]
14. Diabetes care: what should we try to achieve?
O'Connor PJ
J Fam Pract; 1991 Oct; 33(4):343-4. PubMed ID: 1919448
[No Abstract] [Full Text] [Related]
15. Does the choice of treatment for type 2 diabetes affect the physiological response to hypoglycemia?
Peacey SR; Robinson R; Bedford C; Harris ND; Macdonald IA; Holman RR; Heller SR
Diabetes Care; 2000 Jul; 23(7):1022-3. PubMed ID: 10895860
[No Abstract] [Full Text] [Related]
16. Type 2 diabetes: treat to target.
Funnell MM; Kruger DF
Nurse Pract; 2004 Jan; 29(1):11-5, 19-23; quiz 23-5. PubMed ID: 14726786
[TBL] [Abstract][Full Text] [Related]
17. [Combined insulin and sulfonylurea treatment in diabetes mellitus].
Ravina A; Minuhin O
Harefuah; 1986 Jan; 110(1):11-4. PubMed ID: 3514394
[No Abstract] [Full Text] [Related]
18. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.
Bressler R; Johnson DG
Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543
[TBL] [Abstract][Full Text] [Related]
20. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
Eur Heart J; 2008 Jan; 29(2):166-76. PubMed ID: 18156614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
